Short Bowel Syndrome with intestinal failure (SBS-IF) is defined as the reduction of gut function below the minimum necessary for the absorption of macronutrients and/or water and electrolytes, such that intravenous (IV) supplementation is required to maintain health and/or growth.1
SBS-IF is most commonly caused by congenital diseases including:2-5
What if you could free your paediatric patients with short bowel syndrome-intestinal failure (SBS-IF) from parenteral nutrition/IV fluids?
It may be possible with Revestive8
Revestive is the first and only long-term therapy indicated for the treatment of patients with SBS-IF.8-11
In children with SBS-IF*, Revestive reduced PN/IV requirements11
At 24 weeks, 69% of patients treated with Revestive at the approved dose (0.05 mg/kg/day) achieved at least a 20% reduction from baseline in weekly PN/IV volume (n=26 patients)1,11
Revestive was well tolerated across multiple clinical trials in adults and children with short bowel syndrome intestinal
In two completed clinical trials§ in children aged 1–17 years-old with short bowel syndrome-intestinal failure treated with Revestive for up to 6 months:8
Long-term safety data are not yet available for the paediatric population.
Revestive is given by subcutaneous injection once daily.
The recommended dose is 0.05 mg/kg.
Two vial sizes are available:
Vials should be reconstituted with the supplied solvent (0.5 mL).
The reconstituted solution should be administered by subcutaneous injection once daily, alternating sites between 1 of the 4 quadrants of the abdomen. In case the injection into the abdomen is hampered by pain, scarring or hardening of the tissue, the thigh can also be used.
Revestive should not be administered intravenously or intramuscularly.
If a dose is missed, that dose should be injected as soon as possible on that day.
Dosing table: 1.25 mg vial
|BODY WEIGHT||1.25 mg/0.5 mL|
Volume to be injected
|5-6 kg||0.10 ml|
|7-8 kg||0.14 ml|
|9-10 kg||0.18 ml|
|11-12 kg||0.22 ml|
|13-14 kg||0.26 ml|
|15-16 kg||0.30 ml|
|17-18 kg||0.34 ml|
|19-20 kg||0.38 ml|
|>20 kg||Use the 5mg strength vial|
Dosing table: 5.0 mg vial
|BODY WEIGHT||5 mg/0.5 mL|
Volume to be injected
|10-11 kg||0.05 ml|
|12-13 kg||0.06 ml|
|14-17 kg||0.08 ml|
|18-21 kg||0.10 ml|
|22-25 kg||0.12 ml|
|26-29 kg||0.14 ml|
|30-33 kg||0.16 ml|
|34-37 kg||0.18 ml|
|38-41 kg||0.20 ml|
|42-45 kg||0.22 ml|
|46-49 kg||0.24 ml|
|≥50 kg||See “Adults” section|
A treatment period of 6 months is recommended after which treatment effect should be evaluated. In children below the age of two years, treatment should be evaluated after 12 weeks. There are no data available in paediatric patients after 6 months.
*Children with SBS-IF aged 1 – 17 (<18) years, all patients were unable to reduce their PN/IV dependence for at least 3 months prior to study entry.
** Weight normalised reduction.
*** Standard deviation for Revestive: -1.3±2. 6.6 days/week baseline PN/IV requirement for Revestive study population, 6.6 days/week baseline PN/IV requirement for SOC study population.
† Patients treated with Revestive 0.05 mg/kg/day.
‡ Standard deviation for Revestive: -41.6±28.90; SOC: -10.2±13.5926.
§ In a 21-day, Phase II, open-label, multicentre, dose-ranging study evaluating the safety and effect of Revestive in 17 patients with SBS-IF, treatment with Revestive at doses from 0.03 to 0.15 mg/kg/day in single or divided doses. 8 of 10 patients with end jejunostomy were biopsied and found to
have increased intestinal villus height and crypt depth, compared with baseline.
GLP-2= glucagon-like peptide-2; SBS-IF= short bowel syndrome – intestinal failure
The information on this website is intended for an international healthcare professional audience outside of the United States, United Kingdom, and Ireland only.